Answers are grounded in this paper and cite their sources.
Ceftazidime-avibactam (CAZ-AVI) is a novel cephalosporin beta lactamase inhibitor combination that has shown activity against carbapenem-resistant Enterobactericeae. Data are limited on its utilization in the treatment of carbapenem-resistant Klebsiella pneumoniae osteomyelitis in solid organ transplant patients. We describe a case report on the use of CAZ-AVI in the treatment of vertebral osteomyelitis in a renal transplant recipient.
No takes yet. Share an insight, caveat, or question.
Cani et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: